National Cancer Institute (NCI): Mesothelioma, Malignant trials

The registry lists 43 Mesothelioma, Malignant studies with National Cancer Institute (NCI) as lead sponsor. 2 are open to participants now and 20 have results posted.

Early Phase 1 1Phase 1 22Phase 2 24No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage MesotheliomaRecruitingNCT05960773Phase 2
• Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung LiningRecruitingNCT00242723
• Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant MesotheliomaTerminatedNCT04840615Phase 1Results posted
• Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant MesotheliomaTerminatedNCT03644550Phase 2Results posted
• Olaparib in People With Malignant MesotheliomaCompletedNCT03531840Phase 2Results posted
• Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal MesotheliomaTerminatedNCT03436732Phase 1Results posted
• Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal CarcinomasTerminatedNCT03233724Phase 1/2Results posted
• Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant MesotheliomaActive, not recruitingNCT03228537Phase 1Results posted
• Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural MesotheliomaActive, not recruitingNCT03126630Phase 1/2Results posted
• Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant MesotheliomaCompletedNCT02798536Phase 1Results posted
• Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or CarboplatinActive, not recruitingNCT02535312Phase 1/2Results posted
• Tivantinib in Treating Patients With Previously Treated Malignant MesotheliomaTerminatedNCT01861301Phase 2Results posted
• CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic CancerTerminatedNCT01583686Phase 1/2Results posted
• SS1P and Pentostatin Plus Cyclophosphamide for MesotheliomaCompletedNCT01362790Phase 1/2Results posted
• Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With ChemotherapyCompletedNCT01160458Phase 2Results posted
• Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural MesotheliomaActive, not recruitingNCT01064648Phase 1/2Results posted
• Pazopanib in Treating Patients With Malignant Pleural MesotheliomaCompletedNCT00459862Phase 2Results posted
• Sunitinib in Treating Patients With Advanced Malignant Pleural MesotheliomaCompletedNCT00392444Phase 2Results posted
• PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By SurgeryCompletedNCT00365053Phase 2Results posted
• Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By SurgeryCompletedNCT00309946Phase 2Results posted
• S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By SurgeryCompletedNCT00243074Phase 2Results posted
• Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and ChemotherapyCompletedNCT00004547Phase 2Results posted
• Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage MesotheliomaWithdrawnNCT06654050Phase 2
• Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing MesothelinWithdrawnNCT05375825Phase 1
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial CancerActive, not recruitingNCT04491942Phase 1
• Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionWithdrawnNCT02567396Phase 1
• SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural MesotheliomaTerminatedNCT01445392Phase 1
• Amatuximab for High Mesothelin CancersTerminatedNCT01413451Early Phase 1
• Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural MesotheliomasTerminatedNCT01258868Phase 1
• Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural MesotheliomasTerminatedNCT01143545Phase 1
• AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural MesotheliomaWithdrawnNCT01105390Phase 2
• Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.CompletedNCT00107432Phase 2
• Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or MediastinumTerminatedNCT00094978Phase 1
• Immunotoxin Therapy in Treating Patients With Advanced Solid TumorsCompletedNCT00066651Phase 1
• Erlotinib in Treating Patients With Malignant Mesothelioma of the LungCompletedNCT00039182Phase 2
• Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural MalignanciesCompletedNCT00037817Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural CancerTerminatedNCT00028782Not applicable
• Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant MesotheliomaCompletedNCT00027703Phase 2
• Gefitinib in Treating Patients With Malignant MesotheliomaCompletedNCT00025207Phase 2
• Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the PleuraCompletedNCT00019825Phase 1
• Immunotoxin Therapy in Treating Patients With Advanced CancerCompletedNCT00006981Phase 1
• SU5416 in Treating Patients With Malignant MesotheliomaCompletedNCT00006014Phase 2